Evidence map›Paper›PMID 30700265›Full record

ArticleBMC cancer2019

The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.

Amélie Darlix, Christophe Hirtz, Simon Thezenas, Aleksandra Maceski, Audrey Gabelle, Evelyne Lopez-Crapez, Hélène De Forges, Nelly Firmin, Séverine Guiu, William Jacot and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Tau Isoforms: Gaining Insight intoInternational journal of molecular sciences · 2022
    Review
  13. The road-map for establishment of a prognostic molecular marker panel in glioma using liquid biopsy: current status and future directions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Amélie DarlixDepartment of Medical Oncology, Institut du Cancer de Montpellier, University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France. amelie.darlix@icm.unicancer.fr.ORCID http://orcid.org/0000-0003-1384-1709
Christophe HirtzLaboratoire de Biochimie et Protéomique Clinique, University of Montpellier, Institute of Regenerative Medicine - Biotherapy IRMB, CHU Montpellier, INSERM, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
Simon ThezenasBiometrics Unit, Institut du Cancer de Montpellier, University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
Aleksandra MaceskiLaboratoire de Biochimie et Protéomique Clinique, University of Montpellier, Institute of Regenerative Medicine - Biotherapy IRMB, CHU Montpellier, INSERM, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
Audrey GabelleMemory Resources and Research Center, University of Montpellier MUSE, CHU Montpellier, 80 avenue Augustin Fliche, 34295, Montpellier, France.
Evelyne Lopez-CrapezTranslational Research Unit, Institut du Cancer de Montpellier, University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
Hélène De ForgesClinical Research Unit, Institut Régional du Cancer de Montpellier, University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
Nelly FirminDepartment of Medical Oncology, Institut du Cancer de Montpellier, University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
Séverine GuiuDepartment of Medical Oncology, Institut du Cancer de Montpellier, University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
William JacotDepartment of Medical Oncology, Institut du Cancer de Montpellier, University of Montpellier, 208 Avenue des Apothicaires, 34298, Montpellier, France.
Sylvain LehmannLaboratoire de Biochimie et Protéomique Clinique, University of Montpellier, Institute of Regenerative Medicine - Biotherapy IRMB, CHU Montpellier, INSERM, 80 Avenue Augustin Fliche, 34295, Montpellier, France.
Université de Montpellier · FRInserm · FR

Funding

SIRIC Montpellier Cancer INCa-DGOS-Inserm 6045
6 · The paper itself

Abstract

backgroundMetastatic breast cancer (MBC) prognosis is variable, depending on several clinical and biological factors. A better prediction of a patient's outcome could allow for a more accurate choice of treatments. The role of serum biomarkers in predicting outcome remains unclear in this setting. Tau, a microtubule-associated protein, is a neuronal marker that is also expressed in normal breast epithelial cells and cancer cells. Its tissue expression is associated with prognosis in MBC. However, the prognostic value of Tau serum levels in these patients is unknown. We aimed at evaluating the prognostic value of Tau (and other classical biomarkers) in MBC patients, and to assess its association with the presence of brain metastases (BM).

methods244 MBC patients treated at our institution (2007-2015) were retrospectively selected. The usual MBC clinical and pathological variables were collected, altogether with CA15-3, CEA and HER2 extra-cellular domain (ECD) serum levels. Tau serum levels were measured with a novel immunoassay (digital ELISA) using Single Molecule Array (Simoa) technology. Overall survival (OS) was estimated with the Kaplan-Meier method. To investigate prognostic factors, a multivariate analysis was performed. Cut-offs were set using the Youden index method associated with receiver-operating characteristics (ROC) curves to evaluate the accuracy of biomarkers to identify patients with BM.

resultsWith a median follow-up of 40.8 months, median OS was 15.5 months (95%CI 12.4-20.2). Elevated serum levels of Tau were independently associated with a poor outcome in the whole population as well as in patients with (n = 86) and without BM (n = 158). Median serum Tau levels tended to be higher in patients with BM (p = 0.23). In univariate analysis, patients with BM had an increased risk of serum Tau > 3.17 pg/mL (OR = 2.2, p = 0.049). In multivariate analysis, high values of Tau (OR = 3.98, p = 0.034) accurately identified patients with BM in our cohort.

conclusionsTau is a new biomarker of interest in MBC. Its serum level could represent an independent prognostic factor in these patients (both with and without BM). It also seems to be associated with the presence of BM. A validation of these results in an independent set of MBC patients is necessary to confirm these findings.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBrain NeoplasmsBreast NeoplasmsFemaleHumansMiddle AgedPredictive Value of TestsPrognosisRetrospective StudiesSurvival Analysistau ProteinsBiomarkers, TumorMAPT protein, humantau ProteinsBrain metastasesBreast cancerPredictive factorsPrognostic factorsTau proteinTumor markers

Identifiers

PMID30700265
PMCPMC6354387
OpenAlexW2946996794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.